News

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 1, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 27, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 16, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast Today, November 8 th , at 5:00 p.m. ET IRVINE, Calif. --(BUSINESS WIRE)--Nov. 8, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 7, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye,
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 1, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2017 financial results will be released after the market closes on Wednesday, November 8, 2017 . Following the release, the Company will host a
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice President of Medical Affairs
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 30, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa™ (netarsudil ophthalmic solution) 0.02%
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 13, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other
View HTML
Toggle Summary Aerie Pharmaceuticals Stock Trading Halted Today
FDA Advisory Committee to Review New Drug Application for Rhopressa™ (netarsudil ophthalmic solution) 0.02% IRVINE, Calif. --(BUSINESS WIRE)--Oct. 13, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery,
View HTML